NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Medicinova, Inc. MNOV
19 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$409,657
EPS · FY25
$-0.24
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-25.5%
Net margin · FY25
-2928.8%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 409,657.00
Revenue, FY2025 · full 19-year series below
Revenue
Net income
The company lost 2929 cents on every revenue dollar this year.
Per share
USD -0.24
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-25.5%
Return on equity, FY2025
ROE
Operating margin-3242.5%
Net margin-2928.8%
Return on assets-23.6%
Each USD of equity lost 26 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.05B
Shares outstanding, FY2025
Change, 5 years+9.3%
Change, 10 years+64.3%
The share count grew 9% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 45.6M
total assets, end of FY2025
Total assetsUSD 45.6M
EquityUSD 41.6M
CashUSD 30.8M
Current ratio8.16×
Equity funds 91% of total assets.
History
19 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
0.0
·
0.0
·
0.0
·
·
·
·
·
·
·
0.0
0.0
·
·
·
·
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
Income tax $B
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
−0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.24
−0.23
−0.17
−0.29
−0.21
−0.31
−0.30
−0.36
−0.32
−0.33
−0.33
−0.38
−0.19
−0.66
−1.20
−1.63
−1.68
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−25.5
−19.2
−12.9
−18.3
−13.1
−18.9
−17.5
−26.3
−30.5
−32.3
−32.3
−38.8
−20.0
−57.1
−73.6
−62.4
−46.3
−38.2
−73.4
Shares out B
0.05
0.05
0.05
0.05
0.05
0.05
0.04
0.04
0.04
0.03
0.03
0.02
0.02
0.02
0.02
0.01
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
47 of 47
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed